Original Source(s)
Related Content
AD Not Linked to Early CV Risk Markers
Repeated assessments from childhood to early adulthood did not identify consistent cardiometabolic risk patterns by disease activity or severity.
May 27, 2026
-
5 min
FDA Expands Afrezza to Pediatric Diabetes
The decision was supported by the phase 3 INHALE-1 trial and additional long-term safety, efficacy, and exposure data.
May 29, 2026
-
3 min